Table 2.
Clinical studies of ofatumumab combination therapy in relapsed/refractory CLL
| Study | Phase | Treatment | n | ORR (%) | CR (%) | Median PFS | Median OS |
|---|---|---|---|---|---|---|---|
| Cortelezzi et al24 | II | Ofa and Benda | 47 | 72 | 17 | 23.6 months | 83.6% at 24.2 months |
| Offner et al25 | II | Ofa and Benda in untreated and relapsed | 97 | NR | NR | ||
| 44 un | 95 un | 43 un | |||||
| 53 rel | 74 rel | 11 rel | |||||
| Doubek et al26 | II | Ofa and dexamethasone | 33 | 67 | 15 | 10 months | 34 months |
| Del (17p) 63 | Del (17p) 25 | ||||||
| Costa et al29 | II | Sequential treatment with Ofa and lenalidomide | 21 | 47.6 | ND | ND | 21.5 months |
| Jaglowski et al30 | IB/II | Ofa and ibrutinib | 71 | 83.3 | 1.5 | 12 months | NR |
Abbreviations: CLL, chronic lymphocytic leukemia; ORR, overall response rate; CR, complete response; PFS, progression-free survival; OS, overall survival; Ofa, ofatumumab; Benda, bendamustine; ND, no data; NR, not reached; Del, deleted; un, untreated; rel, relapsed.